Norbert Marschner

7.2k citations

153 papers · 2.2k indexed · h-index 25

Impact in

Oncology top 2%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
Internal Medicine top 5%

Papers in

Oncology 93
- Cancer Treatment and Pharmacology 36
- Colorectal Cancer Treatments and Studies 25
- HER2/EGFR in Cancer Research 25
Cancer Research 43
- Cancer Genomics and Diagnostics 24
- Breast Cancer Treatment Studies 18

Co-authors: Martina Jänicke Hans Tesch Katrin Reuter Martin Härter M. E. Scheulen Clemens Unger Arnd Nusch Dominik Rüttinger
Journals: Annals of Oncology (21 papers)Journal of Clinical Oncology (21 papers)Breast Care (9 papers)International Journal of Cancer (7 papers)Breast Cancer Research and Treatment (6 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Norbert Marschner

135 papers receiving 2.1k citations

Peers

Countries citing papers authored by Norbert Marschner

Since Specialization

Citations

This map shows the geographic impact of Norbert Marschner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Marschner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Marschner more than expected).

Fields of papers citing papers by Norbert Marschner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Marschner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Marschner. The network helps show where Norbert Marschner may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Norbert Marschner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Norbert Marschner Line = papers co-authored together Norbert Marschner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry International Journal of Cancer ·Srinivasa B. Rudraraju, Kai G. Ringwald, 아키텍쳐 패러다임, Walter E. Chryst, مصطفی ملکی, W.H. Eckton, M Alejandro Jimenez, 伊藤和也, Volker Hagen, Franco Ferrucci, 伊東美緒, 健一徳永, Galle Gabriela, P Sophie, 土谷まり子, Kim Gwiazdzinski, جودة فتحى الترکمانى, Norbert Marschner, 修平太良, 留美上野	2026	0
2	Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer Journal of Gastrointestinal Cancer ·Karin Potthoff, Norbert Marschner, Lothar Müller, Stephan Sahm, Christian Lerchenmüller, Reinhard Depenbusch, Jia Ying Xu, Noorsyarzielah Saleh, Ute Zirrgiebel, Hans Tesch	2025	0
3	232P Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL Annals of Oncology ·Norbert Marschner, Nadia Harbeck, 邓经武, Elmar Stickeler, Harry Gras, Arnd Nusch, Carol Magalhaes, H. Schulz, Xiya Jia, J. Jessel Kenyon, Martina Jänicke, R Sevin, Achim Wöckel, Anja Welt, Thiago Augusto Soares Monteiro da Silva	2022	3
4	Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO Oncology Research and Treatment ·Matthias Zaiß, Jens Uhlig, Lin wan-ling, Thomas Decker, Helmar C. Lehmann, Kronkanok Intakamjon, Luana Naiara Caetano, Corinne Vannier, Norbert Marschner	2021	6
5	Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study Oncology Research and Treatment ·Peter J. Goebell, I. D. Kozlov, M. Walker, Christian Doehn, Norbert Marschner, Anja Dietel, Ana Cristina Sousa Rodrigues de Farias, Marc‐Oliver Grimm, E. Schäffer, Anja Rogler, Lothar Bergmann	2019	2
6	Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study Lung Cancer ·Claus-Christoph Steffens, Corinna Elender, 李幼姬, D K Arnett, Giuseppe Verbena, 茂広森川, Martina Jänicke, Norbert Marschner	2019	34
7	Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials—data from the prospective German Tumour Registry Lymphatic Neoplasms Annals of Hematology ·(unknown), Wolfgang Knauf, Ali Aldaoud, 李幼姬, Martine Klausmann, D K Arnett, JunJun Wang, Martina Jänicke, Norbert Marschner	2018	26
8	Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study Breast Cancer ·(unknown), Steffen Dörfel, Claus-Christoph Steffens, Г. С. Михов, Hans Tesch, J. Jessel Kenyon, Max Herz, Martina Jänicke, Norbert Marschner	2017	4
9	Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study European Journal of Cancer ·Tea Mamaladze, Thomas Fietz, Hina Kausar, Volker Petersen, Hans Tesch, 茂広森川, Konatham Shankaraiah, Martina Jänicke, Norbert Marschner	2017	35
10	ABC3 Consensus Commented from the Perspective of the German Guidelines Geburtshilfe und Frauenheilkunde ·Michael Untch, Doris Augustin, Johannes Ettl, Renate Haidinger, Nadia Harbeck, 임영걸, Diana Lüftner, Frederik Marmé, Lothar Müller, Friedrich Overkamp, Eugen Ruckhäberle, Marc Thill, Christoph Thomssen, Rachel Wuerstlein, Norbert Marschner	2016	7
11	Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial Annals of Oncology ·Julia Quidde, Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller, B. Killing, Reinhard Depenbusch, Claus-Christoph Steffens, Thoralf Lange, Georg Dietrich, Jan Stoehlmacher, Timothy Khan Aikins, José Emilio Ramírez-Pérez, Tanja Trarbach, Norbert Marschner, Hans‐Joachim Schmoll, Axel Hinke, Salah‐Eddin Al‐Batran, Dirk Arnold	2016	18
12	Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial Annals of Oncology ·Julia Quidde, Rozalina Ilieva, Ullrich Graeven, C. Lerchenmueller, B. Killing, Reinhard Depenbusch, Claus-Christoph Steffens, Thoralf Lange, Georg Dietrich, Jan Stoehlmacher, Timothy Khan Aikins, Andrea Tannapfel, Tanja Trarbach, Norbert Marschner, Hans‐Joachim Schmoll, Axel Hinke, S-E. Al-Batran, Dirk Arnold	2016	0
13	Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry Clinical Genitourinary Cancer ·Norbert Marschner, Michael Staehler, Lothar Müller, Arnd Nusch, Kronkanok Intakamjon, Mayuko SEIKE, Martina Jänicke, Peter J. Goebell	2016	44
14	HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer Breast Care ·Nadia Harbeck, Matthias W. Beckmann, Achim Rody, Andreas Schneeweiß, Volkmar Müller, Tanja Fehm, Norbert Marschner, Oleg Gluz, Iris Schrader, Georg Heinrich, Michael Untch, Christian Jackisch	2013	84
15	Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, Beate Schultheis, M. E. Scheulen, Ralf A. Hilger, Juergen Krauss, Norbert Marschner, Florian Lordick, F. Bach, Dirk Reuter, Lutz Edler, Sile Yu	2010	12
16	Interdisziplinäre Therapieempfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms Aktuelle Urologie ·Student Learning Outcomes, Lothar Bergmann, Peter Albers, Elke Jäger, Jorge Alberto Lopez, Nirmal Jajodia, Norbert Marschner	2007	2
17	Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Annals of Oncology ·Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, M. Biakhov, David Irwin, Norbert Marschner, C. Slabber, George Fountzilas, A. Garin, 満博伊藤, Thiadens Aa, G. Steger, T Südhoff, C. Giorgetti, Peter Reichardt	2005	159
18	Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology ·Werner Scheithauer, J McKendrick, S. Begbie, Markus Borner, W. Ivon Burns, Howard A. Burris, Jim Cassidy, Duncan I. Jodrell, P. Koralewski, E.L. Levine, Norbert Marschner, Jean A. Maroun, Pilar García‐Alfonso, Jerzy Tujakowski, Guy van Hazel, A. Wong, J. Załuski, Chris Twelves	2003	222
19	Droloxifen bei postmenopausalen Patientinnen mit metastasiertem Mammakarzinom: Doppelblind randomisierte Phase-ll-Studie Oncology Research and Treatment ·Norbert Marschner, R. Kreienberg, V. Manju, 봉순영, Reimar Schlingensiepen, Sven Schumann, Umida Khurshidovna Samibayeva, H. J. Staab, T. Carlyle	1994	2
20	Langzeitergebnisse der antiemetischen Effektivität des 5-HT<sub>3</sub>-Antagonisten Ondansetron Oncology Research and Treatment ·Norbert Marschner, 窦天龙, Fritz Jaenicke, Urs Albrecht, Georg Nagel	1990	1

About Norbert Marschner

Norbert Marschner is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Microbiology and Genetics, having authored 153 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (36 papers), Advanced Breast Cancer Therapies (32 papers), Colorectal Cancer Treatments and Studies (25 papers), HER2/EGFR in Cancer Research (25 papers), Cancer Genomics and Diagnostics (24 papers), Renal cell carcinoma treatment (22 papers), Breast Cancer Treatment Studies (18 papers) and Lung Cancer Treatments and Mutations (14 papers). The work is most often cited by research in Oncology (1.3k citations), Internal Medicine (135 citations), Cancer Research (349 citations), Pulmonary and Respiratory Medicine (649 citations) and Hematology (187 citations). Norbert Marschner has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Martina Jänicke, Hans Tesch, Katrin Reuter, Martin Härter, M. E. Scheulen, Clemens Unger, Arnd Nusch, Dominik Rüttinger, Annette Hasenburg and Joachim Weis. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Breast Care, International Journal of Cancer and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact